Here are the S-3 shelf registrations from Jupiter Neurosciences, Inc. (JUNS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow JUNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JUNS filings page.
Jupiter Neurosciences, Inc. (JUNS) is registering up to 132,867 shares of common stock for resale by PharmAla Biotech Holdings Inc.; Jupiter will receive no proceeds from PharmAla’s sales. Issued to PharmAla on August 20, 2026, the shares formed part of the consideration for an exclusive U.S. license covering products incorporating or derived from ALA-002.
The license agreement required an upfront payment of $3,333,333 and provides for development milestone payments totaling up to $23,333,333, commercialization milestone payments totaling up to $73,333,333, and a 3% royalty on net sales beginning in the calendar quarter when the third commercialization milestone becomes payable.
Management says recurring operating losses, negative operating cash flows and reliance on financing raise substantial doubt about Jupiter’s ability to continue as a going concern. Nasdaq staff determined on August 27, 2026, to delist Jupiter’s shares because the market value of listed securities was below $35,000,000. Jupiter appealed and expects the hearing request to stay further delisting action pending the Panel’s final determination; it separately reported regaining compliance with the minimum bid-price requirement.
Jupiter Neurosciences, Inc. filed a shelf registration on Form S-3 to offer, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, rights and/or units. The shelf permits multiple offerings under prospectus supplements describing specific terms and sale methods.
The company reported 36,281,252 shares of common stock issued and outstanding as of March 31, 2026, a public float of $13,632,945 based on 22,608,533 non-affiliate shares at $0.603 per share as of February 15, 2026, and a last reported sale price of $0.3940 on April 14, 2026. The prospectus states net proceeds will be used for general corporate purposes, including clinical trials and R&D.